Thursday, November 14, 2024

HomeStock MarketRegeneron, Sanofi post mixed data for Dupixent trials (NASDAQ:REGN)

Regeneron, Sanofi post mixed data for Dupixent trials (NASDAQ:REGN)

green arrow up and red arrow down market , 3D illustration rendering

moxumbic

Regeneron (NASDAQ:REGN) and Sanofi (NASDAQ:SNY) on Wednesday announced that a Phase 3 trial for their blockbuster asthma therapy Dupixent for a skin condition known as bullous pemphigoid succeeded, while another for a long-term itching condition failed.

Citing data from their


Source link

Bookmark (0)
Please login to bookmarkClose
RELATED ARTICLES
- Advertisment -spot_img

Most Popular

Sponsored Business

- Advertisment -spot_img